Marksans Pharma has received final approval from US Food & Drugs
Administration for its Abbreviated New Drug Application (ANDA) for over the counter (OTC) Cetirizine Hydrochloride Tablets 5 mg and 10mg.
It is indicated for the treatment of the perennial allergic rhinitis including sneezing, rhinorrhea, postnasal discharge, watery eyes, running nose. The product will be marketed under store brand labels and is comparable to the brand Zyrtec.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
